Ind-Swift Labs.

Who are the top shareholders of the Ind-Swift Labs.?

The top shareholders of Ind-Swift Labs include Essix Biosciences Limited with 36.83%, Wilson Holdings Private Limited at 8.72%, and individual investors holding 37.61%. Additionally, 7 Foreign Institutional Investors own 3.07%, with no pledged promoter holdings or mutual funds involved.

The top shareholders of Ind-Swift Labs include Essix Biosciences Limited, which holds the largest share at 36.83%. Following that, Wilson Holdings Private Limited is the highest public shareholder with an ownership stake of 8.72%. Additionally, individual investors collectively hold 37.61% of the company's shares. The company also has 7 Foreign Institutional Investors (FIIs) holding a total of 3.07%. There are no pledged promoter holdings and no mutual funds currently holding shares in the company.

What does Ind-Swift Labs. do?

Ind-Swift Laboratories Ltd is a micro-cap manufacturer of Active Pharmaceutical Ingredients (APIs) based in Chandigarh, India, with recent net sales of 9 Cr and a market cap of Rs 567 Cr. The company operates two manufacturing facilities and adheres to international standards.

Overview:<BR>Ind-Swift Laboratories Ltd is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) in the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History:<BR>Ind-Swift Laboratories Ltd is part of the Ind-Swift Group and is based in Chandigarh, India. The company operates two advanced manufacturing facilities and adheres to international standards. The latest quarterly results reported net sales and net profit for December 2024.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 9 Cr (Quarterly Results - Dec 2024) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Dec 2024) <BR>Market-cap value: Rs 567 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 8.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.45 <BR>Return on Equity: 10.04% <BR>Price to Book: 0.63 <BR><BR>Contact Details:<BR>Address: SCO 850 Shivalik Enclave, NAC Manimajra Chandigarh Chandigarh (U T): 160101 <BR>Phone: 91-0172-5061850/2730920 <BR>Email: investor@indswiftlabs.com <BR>Website: http://www.indswiftlabs.com

Who are in the management team of Ind-Swift Labs.?

As of March 2019, the management team of Ind-Swift Labs includes N R Munjal (Chairman & Managing Director), Himanshu Jain (Joint Managing Director), and several independent directors, totaling a diverse group that oversees the company's governance and operations.

As of March 2019, the management team of Ind-Swift Labs includes:<BR><BR>1. N R Munjal - Chairman & Managing Director<BR>2. N R Munjal - Vice Chairman & Managing Director<BR>3. Himanshu Jain - Joint Managing Director<BR>4. Pradeep Verma - Company Secretary<BR>5. Rishav Mehta - Executive Director<BR>6. Sahil Munjal - Executive Director<BR>7. Prabhat Khurana - Independent Director<BR>8. S P Sharma - Independent Director<BR>9. Neerja Chathley - Independent Director<BR>10. Ashwani K Vig - Independent Director<BR>11. Rajendra Kumar Gupta - Independent Director<BR><BR>This team comprises a mix of executive and independent directors, contributing to the governance and management of the company.

Has Ind-Swift Labs. declared dividend?

Ind-Swift Laboratories Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of September 20, 2011. However, the dividend yield is 0%, and total returns have varied significantly, showing strong long-term performance despite recent declines.

Ind-Swift Laboratories Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 20 Sep 11<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -15.31%, with a dividend return of 0%, resulting in a total return of -15.31%.<BR><BR>Over the past year, the price return was -14.71%, and with a dividend return of 0%, the total return was -14.71%.<BR><BR>In the 2-year period, the price return was 30.56%, with a dividend return of 0%, leading to a total return of 30.56%.<BR><BR>For the 3-year period, the price return was 56.82%, while the dividend return remained 0%, resulting in a total return of 56.82%.<BR><BR>In the 4-year period, the price return was 8.6%, with a dividend return of 0%, giving a total return of 8.6%.<BR><BR>Lastly, over the 5-year period, the price return was 234.33%, and the dividend return was 0%, resulting in a total return of 234.33%.<BR><BR>Overall, while Ind-Swift Laboratories Ltd has declared a dividend, the dividend yield is 0%, indicating that the dividend has not contributed to returns in recent periods. The total returns show significant variability, with strong performance over the longer term despite recent declines in price returns.

Who are the peers of the Ind-Swift Labs.?

Ind-Swift Labs. peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Valiant Laborato, Albert David, Medico Remedies, and Zim Laboratories. Ind-Swift Labs. has below average management risk, growth, and capital structure compared to its peers, with a 1-year return of -21.31%.

Peers: The peers of Ind-Swift Labs. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Valiant Laborato, Albert David, Medico Remedies, and Zim Laboratories.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Albert David, Medico Remedies, and Zim Laboratories, and Below Average management risk is noted for Ind-Swift Labs., Valiant Laborato. In terms of Growth, Excellent growth is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is reported for Ind-Swift Labs., Divi's Lab., Torrent Pharma, Valiant Laborato, and the rest. For Capital Structure, Excellent capital structure is attributed to Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, Good capital structure is noted for Torrent Pharma and Medico Remedies, while Ind-Swift Labs., Valiant Laborato, and Zim Laboratories have Below Average capital structure.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Ind-Swift Labs. has the lowest at -21.31%. Ind-Swift Labs.'s return is significantly lower than its peers. Additionally, the six-month return is negative for Ind-Swift Labs., Valiant Laborato, Albert David, and Zim Laboratories.

How big is Ind-Swift Labs.?

As of 24th July, Ind-Swift Laboratories Ltd has a market capitalization of 644.00 Cr, with recent net sales of 447.12 Cr and a net profit of 354.00 Cr. The company's shareholder's funds are 931.46 Cr, and total assets amount to 1,133.25 Cr.

As of 24th July, Ind-Swift Laboratories Ltd has a market capitalization of 644.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 447.12 Cr and a Net Profit of 354.00 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 931.46 Cr and Total Assets of 1,133.25 Cr.

Is Ind-Swift Labs. overvalued or undervalued?

As of August 12, 2025, Ind-Swift Labs. is considered risky and overvalued with a PE ratio of 59.73, a negative EV to EBITDA of -5.91, and a significant decline of 39.74% over the past year, contrasting sharply with its peers Sun Pharma and Cipla, which have lower PE ratios and are deemed attractive.

As of 12 August 2025, the valuation grade for Ind-Swift Labs. has moved from attractive to risky, indicating a significant shift in its perceived value. The company is currently considered overvalued, with a PE ratio of 59.73, an EV to EBITDA of -5.91, and a PEG ratio of 0.00, which suggests that the stock may not be justified by its earnings growth potential. <BR><BR>In comparison to its peers, Ind-Swift Labs. has a much higher PE ratio than Sun Pharma (33.93) and Cipla (22.77), both of which are categorized as attractive. Additionally, the company's negative EV to EBITDA ratio raises concerns about its operational profitability relative to its enterprise value. While Ind-Swift Labs. has shown strong returns over the long term, its recent performance has lagged behind the Sensex, particularly over the past year, where it has declined by 39.74% compared to a modest 0.74% gain in the index.

How has been the historical performance of Ind-Swift Labs.?

Ind-Swift Labs has faced significant financial volatility, with net sales dropping from INR 1,709.15 crore in March 2024 to INR 561.71 crore in March 2025, resulting in an operating loss of INR 19.39 crore. Despite a positive profit before tax of INR 257.80 crore in March 2025, overall performance reflects ongoing operational challenges.

Answer:<BR>The historical performance of Ind-Swift Labs shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Ind-Swift Labs experienced a notable decline in net sales from INR 1,709.15 crore in March 2024 to INR 561.71 crore in March 2025, following a peak of INR 1,207.31 crore in March 2023. The total operating income mirrored this trend, dropping to INR 561.71 crore in March 2025 from INR 1,709.15 crore in the previous year. The company's operating profit (PBDIT) also fell sharply, resulting in a loss of INR 19.39 crore in March 2025, compared to a profit of INR 303.06 crore in March 2024. Despite these challenges, profit before tax remained positive at INR 257.80 crore in March 2025, although it decreased from INR 598.22 crore in March 2024. The profit after tax for March 2025 was INR 250.53 crore, down from INR 539.24 crore the previous year. On the balance sheet, total liabilities slightly decreased to INR 1,393.70 crore in March 2025 from INR 1,409.22 crore in March 2024, while total assets also saw a minor decline to INR 1,393.70 crore. Cash flow from operating activities was negative at INR -25.00 crore in March 2025, reflecting ongoing operational challenges. Overall, the financial performance of Ind-Swift Labs indicates a period of significant volatility and operational difficulties in the most recent fiscal year.

Is Ind-Swift Labs. technically bullish or bearish?

As of November 17, 2025, the technical trend has shifted to mildly bearish due to bearish momentum indicated by MACD readings and Bollinger Bands, despite some mixed signals from moving averages and Dow Theory.

As of 17 November 2025, the technical trend has changed from mildly bullish to mildly bearish. The current technical stance is mildly bearish, driven by weekly and monthly MACD readings indicating bearish momentum, along with Bollinger Bands signaling bearish conditions. The KST also reflects a mildly bearish outlook on the weekly and bearish on the monthly. Although the daily moving averages show a mildly bullish trend, the overall indicators suggest weakness. The Dow Theory presents a mixed view with a mildly bearish weekly stance and a mildly bullish monthly stance, adding to the uncertainty. The stock has underperformed against the Sensex across multiple time frames, further supporting the bearish sentiment.

When is the next results date for Ind-Swift Laboratories Ltd?

The next results date for Ind-Swift Laboratories Ltd is January 31, 2026.

The next results date for Ind-Swift Laboratories Ltd is scheduled for January 31, 2026.

Are Ind-Swift Laboratories Ltd latest results good or bad?

Ind-Swift Laboratories Ltd's latest results show impressive year-on-year growth in net profit and revenue, but concerns about thin operating margins and heavy reliance on non-operating income suggest the recovery may not be sustainable. Investors should remain cautious and monitor the company's operational challenges.

Ind-Swift Laboratories Ltd's latest results present a mixed picture. On one hand, the company has reported remarkable year-on-year growth in both net profit and revenue, with net profit increasing by an astonishing 1,848.78% to ₹7.99 crore and revenue growing by 1,176.25% to ₹152.64 crore in Q2 FY26 compared to the same quarter last year. This recovery follows a very weak performance in FY25, indicating a significant turnaround in the company's financials.<BR><BR>However, there are substantial concerns regarding the sustainability of this recovery. The operating margin remains extremely thin at just 0.96%, which is a significant issue for a manufacturing business. This margin has actually decreased from 2.36% in the previous quarter, suggesting operational challenges that need addressing. Additionally, the profit after tax margin of 5.27% has also declined from 5.66% in the prior quarter, raising questions about the quality of earnings.<BR><BR>A critical aspect of the financials is the heavy reliance on non-operating income, which constituted a large portion of the profits. This dependency on other income raises concerns about the core business's ability to generate sustainable profits.<BR><BR>In summary, while the revenue and profit growth figures are impressive on a year-on-year basis, the underlying operational weaknesses and reliance on non-operating income indicate that the results are not entirely positive. Investors may need to be cautious and monitor how the company addresses its operational challenges moving forward.

Should I buy, sell or hold Ind-Swift Laboratories Ltd?

Why is Ind-Swift Laboratories Ltd falling/rising?

As of 01-Feb, Ind-Swift Laboratories Ltd's stock price is Rs 111.20, down 1.89%. Despite significant growth in operating profit, the stock underperforms its sector and faces challenges like high debt and weak long-term fundamentals, contributing to its current decline.

As of 01-Feb, Ind-Swift Laboratories Ltd's stock price is currently at Rs 111.20, reflecting a decrease of Rs 2.14 or 1.89%. This decline can be attributed to several factors. Despite the company reporting a significant growth in operating profit of 217.92% and positive results over the last two consecutive quarters, the stock has underperformed its sector by 1.42% today. <BR><BR>Intraday trading showed volatility, with the stock reaching a high of Rs 118.05 but also dipping to a low of Rs 110, indicating a lack of sustained upward momentum. Furthermore, while the stock has shown positive returns over various periods, including a 24.52% increase over the past month, it has also faced challenges such as a weak long-term fundamental strength, evidenced by a -186.27% CAGR growth in operating profits over the last five years. <BR><BR>The company's high debt to EBITDA ratio of 2.60 times raises concerns about its ability to service debt, and its average return on equity of 6.54% suggests low profitability per unit of shareholders' funds. Additionally, the absence of domestic mutual fund investment, which stands at 0%, may indicate a lack of confidence in the stock's valuation or business prospects. <BR><BR>Overall, while there are positive indicators such as rising investor participation and trading above moving averages, the combination of underperformance against the sector, high debt levels, and weak long-term fundamentals contribute to the current decline in the stock price.

Which are the latest news on Ind-Swift Labs.?